Search

Your search keyword '"Lewis, Basil S."' showing total 334 results
Start Over Author "Lewis, Basil S." Search Limiters Available in Library Collection
334 results on '"Lewis, Basil S."'

1. Timing of Staged Nonculprit Artery Revascularization in Patients With ST-Segment Elevation Myocardial Infarction: COMPLETE Trial

Author

Wood, David A., Cairns, John A., Wang, Jia, Mehran, Roxana, Storey, Robert F., Nguyen, Helen, Meeks, Brandi, Kunadian, Vijay, Tanguay, Jean-Francois, Kim, Hahn-Ho, Cheema, Asim, Dehghani, Payam, Natarajan, Madhu K., Jolly, Sanjit S., Amerena, John, Keltai, Matyas, James, Stefan, Hlinomaz, Ota, Niemela, Kari, AlHabib, Khalid, Lewis, Basil S., Nguyen, Michel, Sarma, Jaydeep, Dzavik, Vladimir, Della Siega, Anthony, and Mehta, Shamir R.

Published
2019
Full Text
View/download PDF

2. Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin

Author

Moayyedi, Paul, Eikelboom, John W., Bosch, Jackie, Connolly, Stuart J., Dyal, Leanne, Shestakovska, Olga, Leong, Darryl, Anand, Sonia S., Störk, Stefan, Branch, Kelley R.H., Bhatt, Deepak L., Verhamme, Peter B., O’Donnell, Martin, Maggioni, Aldo P., Lonn, Eva M., Piegas, Leopoldo S., Ertl, Georg, Keltai, Matyas, Bruns, Nancy Cook, Muehlhofer, Eva, Dagenais, Gilles R., Kim, Jae-Hyung, Hori, Masatsugu, Steg, P. Gabriel, Hart, Robert G., Diaz, Rafael, Alings, Marco, Widimsky, Petr, Avezum, Alvaro, Probstfield, Jeffrey, Zhu, Jun, Liang, Yan, Lopez-Jaramillo, Patricio, Kakkar, Ajay K., Parkhomenko, Alexander N., Ryden, Lars, Pogosova, Nana, Dans, Antonio L., Lanas, Fernando, Commerford, Patrick J., Torp-Pedersen, Christian, Guzik, Tomek J., Vinereanu, Dragos, Tonkin, Andrew M., Lewis, Basil S., Felix, Camilo, Yusoff, Khalid, Metsarinne, Kaj P., Fox, Keith A.A., and Yusuf, Salim

Published
2019
Full Text
View/download PDF

3. Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial

Author

Moayyedi, Paul, Eikelboom, John W., Bosch, Jackie, Connolly, Stuart J., Dyal, Leanne, Shestakovska, Olga, Leong, Darryl, Anand, Sonia S., Störk, Stefan, Branch, Kelly R.H., Bhatt, Deepak L., Verhamme, Peter B., O’Donnell, Martin, Maggioni, Aldo P., Lonn, Eva M., Piegas, Leopoldo S., Ertl, Georg, Keltai, Matyas, Cook Bruns, Nancy, Muehlhofer, Eva, Dagenais, Gilles R., Kim, Jae-Hyung, Hori, Masatsugu, Steg, P. Gabriel, Hart, Robert G., Diaz, Rafael, Alings, Marco, Widimsky, Petr, Avezum, Alvaro, Probstfield, Jeffrey, Zhu, Jun, Liang, Yan, Lopez-Jaramillo, Patricio, Kakkar, Ajay, Parkhomenko, Alexander N., Ryden, Lars, Pogosova, Nana, Dans, Antonio, Lanas, Fernando, Commerford, Patrick J., Torp-Pedersen, Christian, Guzik, Tomek, Vinereanu, Dragos, Tonkin, Andrew M., Lewis, Basil S., Felix, Camilo, Yusoff, Khalid, Metsarinne, Kaj, Fox, Keith A.A., and Yusuf, Salim

Published
2019
Full Text
View/download PDF

5. Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial

Author

Bhatt, Deepak L., Eikelboom, John W., Connolly, Stuart J., Steg, P. Gabriel, Anand, Sonia S., Verma, Subodh, Branch, Kelley R.H., Probstfield, Jeffrey, Bosch, Jackie, Shestakovska, Olga, Szarek, Michael, Maggioni, Aldo Pietro, Widimský, Petr, Avezum, Alvaro, Diaz, Rafael, Lewis, Basil S., Berkowitz, Scott D., Fox, Keith A.A., Ryden, Lars, and Yusuf, Salim

Published
2020
Full Text
View/download PDF

6. Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI)

Author

Bainey, Kevin R., Welsh, Robert C., Connolly, Stuart J., Marsden, Tamara, Bosch, Jackie, Fox, Keith A.A., Steg, P. Gabriel, Vinereanu, Dragos, Connolly, Derek L., Berkowitz, Scott D., Foody, JoAnne M., Probstfield, Jeffrey L., Branch, Kelley R., Lewis, Basil S., Diaz, Rafael, Muehlhofer, Eva, Widimsky, Petr, Yusuf, Salim, Eikelboom, John W., and Bhatt, Deepak L.

Published
2020
Full Text
View/download PDF

7. Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial

Author

Windecker, Stephan, Lopes, Renato D., Massaro, Tyler, Jones-Burton, Charlotte, Granger, Christopher B., Aronson, Ronald, Heizer, Gretchen, Goodman, Shaun G., Darius, Harald, Jones, W. Schuyler, Aschermann, Michael, Brieger, David, Cura, Fernando, Engstrøm, Thomas, Fridrich, Viliam, Halvorsen, Sigrun, Huber, Kurt, Kang, Hyun-Jae, Leiva-Pons, Jose L., Lewis, Basil S., Malaga, German, Meneveau, Nicolas, Merkely, Bela, Milicic, Davor, Morais, João, Potpara, Tatjana S., Raev, Dimitar, Sabaté, Manel, de Waha-Thiele, Suzanne, Welsh, Robert C., Xavier, Denis, Mehran, Roxana, and Alexander, John H.

Published
2019
Full Text
View/download PDF

8. Guía ESC 2020 sobre el diagnóstico y tratamiento del síndrome coronario agudo sin elevación del segmento ST: Grupo de Trabajo de la Sociedad Europea de Cardiología (ESC) para el diagnóstico y tratamiento del síndrome coronario agudo (SCA) en pacientes sin elevación persistente del segmento ST

Author

Collet, Jean-Philippe, Thiele, Holger, Barbato, Emanuele, Barthélémy, Olivier, Bauersachs, Johann, Bhatt, Deepak L., Dendale, Paul, Dorobantu, Maria, Edvardsen, Thor, Folliguet, Thierry, Gale, Chris P., Gilard, Martine, Jobs, Alexander, Jüni, Peter, Lambrinou, Ekaterini, Lewis, Basil S., Mehilli, Julinda, Meliga, Emanuele, Merkely, Béla, Mueller, Christian, Roffi, Marco, Rutten, Frans H., Sibbing, Dirk, and Siontis, George C.M.

Published
2021
Full Text
View/download PDF

9. Guía ESC 2020 para el tratamiento de las cardiopatías congénitas del adulto

Author

Baumgartner, Helmut, De Backer, Julie, Babu-Narayan, Sonya V., Budts, Werner, Chessa, Massimo, Diller, Gerhard-Paul, Iung, Bernard, Kluin, Jolanda, Lang, Irene M., Meijboom, Folkert, Moons, Philip, Mulder, Barbara J.M., Oechslin, Erwin, Roos-Hesselink, Jolien W., Schwerzmann, Markus, Sondergaard, Lars, Zeppenfeld, Katja, Ernst, Sabine, Ladouceur, Magalie, Aboyans, Victor, Alexander, David, Christodorescu, Ruxandra, Corrado, Domenico, D’Alto, Michele, de Groot, Natasja, Delgado, Victoria, Di Salvo, Giovanni, Dos Subira, Laura, Eicken, Andreas, Fitzsimons, Donna, Frogoudaki, Alexandra A., Gatzoulis, Michael, Heymans, Stephane, Hörer, Jürgen, Houyel, Lucile, Jondeau, Guillaume, Katus, Hugo A., Landmesser, Ulf, Lewis, Basil S., Lyon, Alexander, Mueller, Christian E., Mylotte, Darren, Petersen, Steffen E., Petronio, Anna Sonia, Roffi, Marco, Rosenhek, Raphael, Shlyakhto, Evgeny, Simpson, Iain A., Sousa-Uva, Miguel, Torp-Pedersen, Christian Tobias, Touyz, Rhian M., and Van De Bruaene, Alexander

Published
2021
Full Text
View/download PDF

11. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)

Author

Bonaca, Marc P., Nault, Patrice, Giugliano, Robert P., Keech, Anthony C., Pineda, Armando Lira, Kanevsky, Estella, Kuder, Julia, Murphy, Sabina A., Jukema, J. Wouter, Lewis, Basil S., Tokgozoglu, Lale, Somaratne, Ransi, Sever, Peter S., Pedersen, Terje R., and Sabatine, Marc S.

Published
2018
Full Text
View/download PDF

13. Abstract 47: Tapering And Discontinuation Of Background Therapies During The Transition To Rilonacept Monotherapy In Rhapsody, A Phase 3 Clinical Trial Of Rilonacept In Patients With Recurrent Pericarditis

Author

Brucato, Antonio, primary, Wheeler, Alistair, additional, Luis, Sushil A, additional, Abbate, Antonio, additional, Cremer, Paul C, additional, Fang, Fang, additional, Insalaco, Antonella, additional, Lewinter, Martin M, additional, Lewis, Basil S, additional, Lin, David, additional, Nicholls, Stephen J, additional, Chatfield, Jay B, additional, Klein, Allan L, additional, Imazio, Massimo, additional, and Paolini, John F, additional

Published
2022
Full Text
View/download PDF

14. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death

Author

Zeppenfeld, Katja, Tfelt-Hansen, Jacob, de Riva, Marta, Winkel, Bo Gregers, Behr, Elijah R, Blom, Nico A, Charron, Philippe, Corrado, Domenico, Dagres, Nikolaos, de Chillou, Christian, Eckardt, Lars, Friede, Tim, Haugaa, Kristina H, Hocini, Mélèze, Lambiase, Pier D, Marijon, Eloi, Merino, Jose L, Peichl, Petr, Priori, Silvia G, Reichlin, Tobias, Schulz-Menger, Jeanette, Sticherling, Christian, Tzeis, Stylianos, Verstrael, Axel, Volterrani, Maurizio, Cikes, Maja, Kirchhof, Paulus, Abdelhamid, Magdy, Aboyans, Victor, Arbelo, Elena, Arribas, Fernando, Asteggiano, Riccardo, Basso, Cristina, Bauer, Axel, Bertaglia, Emanuele, Biering-Sørensen, Tor, Blomström-Lundqvist, Carina, Borger, Michael A, Čelutkienė, Jelena, Cosyns, Bernard, Falk, Volkmar, Fauchier, Laurent, Gorenek, Bulent, Halvorsen, Sigrun, Hatala, Robert, Heidbuchel, Hein, Kaab, Stefan, Konradi, Aleksandra, Koskinas, Konstantinos C, Kotecha, Dipak, Landmesser, Ulf, Lewis, Basil S, Linhart, Ales, Løchen, Maja-Lisa, Lund, Lars H, Metzner, Andreas, Mindham, Richard, Nielsen, Jens Cosedis, Norekvål, Tone M, Patten, Monica, Prescott, Eva, Rakisheva, Amina, Remme, Carol Ann, Roca-Luque, Ivo, Sarkozy, Andrea, Scherr, Daniel, Sitges, Marta, Touyz, Rhian M, Van Mieghem, Nicolas, Velagic, Vedran, Viskin, Sami, Volders, Paul G A, Pediatrics, Physiology, ACS - Heart failure & arrhythmias, Paediatric Cardiology, Cardiology, and APH - Methodology

Subjects
Genetic testing, Cardiac magnetic resonance, Sudden death, Arrhythmias, Cardiac, Ventricular tachycardia, Primary electrical disease, Guidelines, Recommendations, Chronic coronary artery disease, Risk calculator, Sudden cardiac death, Death, Sudden, Cardiac, Implantable cardioverter defibrillator, Ventricular arrhythmia, Humans, Catheter ablation, Anti-arrhythmic drugs, Ventricular fibrillation, Cardiology and Cardiovascular Medicine, 610 Medicine & health, Cardiomyopathies, Premature ventricular complex, Risk stratification
Published
2022

15. The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid, diabetes, and antithrombotic trials

Author

Drexel, Heinz, Lewis, Basil S, Rosano, Giuseppe M C, Saely, Christoph H, Tautermann, Gerda, Huber, Kurt, Dopheide, Joern F., Kaski, Juan Carlos, Mader, Arthur, Niessner, Alexander, Savarese, Gianluigi, Schmidt, Thomas A, Semb, AnneGrete, Tamargo, Juan, Wassmann, Sven, Kjeldsen, Keld Per, Agewall, Stefan, and Pocock, Stuart J

Subjects
610 Medicine & health
Abstract

This review article aims to explain the important issues that data safety monitoring boards (DSMB) face when considering early termination of a trial and is specifically addressed to the needs of clinical and research cardiologists. We give an insight into the overall background and then focus on the three principal reasons for stopping trials, i.e. efficacy, futility, and harm. The statistical essentials are also addressed to familiarize clinicians with the key principles. The topic is further highlighted by numerous examples from lipid trials and antithrombotic trials. This is followed by an overview of regulatory aspects, including an insight into industry–investigator interactions. To conclude, we summarize the key elements that are the basis for a decision to stop a randomized clinical trial (RCT).

Published
2021

16. Pro

Author

Thiele, Holger, Sibbing, Dirk, Barthélémy, Olivier, Bauersachs, Johann, Bhatt, Deepak L., Dendale, Paul, Dorobantu, Maria, Edvardsen, Thor, Folliguet, Thierry, Gale, Chris P., Gilard, Martine, Jobs, Alexander, Jüni, Peter, Lambrinou, Ekaterini, Lewis, Basil S., Mehilli, Julinda, Meliga, Emanuele, Merkely, Béla, Mueller, Christian, Roffi, Marco, Rutten, Frans H., Siontis, George C. M., Barbato, Emanuele, and Collet, Jean-Philippe

Subjects
Ticagrelor, Antiplatelet therapy, Health Sciences, Angiography, Strategy, Open-label, Prasugrel, Medical and Health Sciences, Pretreatment, Percutaneous coronary intervention, Myocardial-infarction, Clopidogrel
Published
2021

18. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)

Author

Roffi, Marco, Patrono, Carlo, Collet, Jean-Philippe, Mueller, Christian, Valgimigli, Marco, Andreotti, Felicita, Bax, Jeroen J., Borger, Michael A., Brotons, Carlos, Chew, Derek P., Gencer, Baris, Hasenfuss, Gerd, Kjeldsen, Keld, Lancellotti, Patrizio, Landmesser, Ulf, Mehilli, Julinda, Mukherjee, Debabrata, Storey, Robert F., Windecker, Stephan, Baumgartner, Helmut, Gaemperli, Oliver, Achenbach, Stephan, Agewall, Stefan, Badimon, Lina, Baigent, Colin, Bueno, Héctor, Bugiardini, Raffaele, Carerj, Scipione, Casselman, Filip, Cuisset, Thomas, Erol, Çetin, Fitzsimons, Donna, Halle, Martin, Hamm, Christian, Hildick-Smith, David, Huber, Kurt, Iliodromitis, Efstathios, James, Stefan, Lewis, Basil S., Lip, Gregory Y. H., Piepoli, Massimo F., Richter, Dimitrios, Rosemann, Thomas, Sechtem, Udo, Steg, Ph. Gabriel, Vrints, Christian, and Luis Zamorano, Jose

Published
2016
Full Text
View/download PDF

19. The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study

Author

Jankowska, Ewa A, Kirwan, Bridget-Anne, Kosiborod, Mikhail, Butler, Javed, Anker, Stefan D, McDonagh, Theresa, Dorobantu, Maria, Drozdz, Jarosław, Filippatos, Gerasimos, Keren, Andre, Khintibidze, Irakli, Kragten, Hans, Martinez, Felipe A, Metra, Marco, Milicic, Davor, Nicolau, José C, Ohlsson, Marcus, Parkhomenko, Alexander, Pascual-Figal, Domingo A, Ruschitzka, Frank, Sim, David, Skouri, Hadi, van der Meer, Peter, Lewis, Basil S, Comin-Colet, Josep, von Haehling, Stephan, Cohen-Solal, Alain, Danchin, Nicolas, Doehner, Wolfram, Dargie, Henry J, et al, University of Zurich, and Jankowska, Ewa A

Subjects
10209 Clinic for Cardiology, 610 Medicine & health, 2705 Cardiology and Cardiovascular Medicine
Published
2021

20. 2020 ESC Guidelines on the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndrome Working Group of the European Society of Cardiology (ESC) for the diagnosis and treatment of acute coronary syndrome (ACS) in patients without persistent ST segment elevation

Author

Collet, Jean-Philippe, Thiele, Holger, Barbato, Emanuele, Barthelemy, Olivier, Bauersachs, Johann, Bhatt, Deepak L., Dendale, Paul, Dorobantu, Maria, Thor Edvardsen, Folliguet, Thierry, Gale, Chris P., Gilard, Martine, Jobs, Alexander, Juni, Peter, Lambrinou, Ekaterini, Lewis, Basil S., Mehilli, Julinda, Meliga, Emanuele, Merkely, Bela, Mueller, Christian, Roffi, Marco, Rutten, Frans H., Sibbing, Dirk, and Siontis, George C. M.

Subjects
Sensitivity-Cardiac Troponin, Atrial-Fibrillation Patients, Acute Myocardial-Infraction, Health Sciences, Dual-Antiplatelet Therapy, Early Rule-Out, Cardiovascular Magnetic-Resonance, Optical Coherence Tomography, Fractional Flow Reserve, Medical and Health Sciences, Early Invasive Strategy, Long-Term Survival
Published
2021

21. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)

Author

Collet, Jean-Philippe, Thiele, Holger, Barbato, Emanuele, Barthélémy, Olivier, Bauersachs, Johann, Bhatt, Deepak L., Dendale, Paul, Dorobantu, Maria, Edvardsen, Thor, Folliguet, Thierry, Gale, Chris P., Gilard, Martine, Jobs, Alexander, Jüni, Peter, Lambrinou, Ekaterini, Lewis, Basil S., Mehilli, Julinda, Meliga, Emanuele, Merkely, Béla, Mueller, Christian, Roffi, Marco, Rutten, Frans H., Sibbing, Dirk, and Siontis, George C. M.

Subjects
High-sensitivity troponin, Ticagrelor, Chest pain unit, Platelet inhibition, Atherothrombosis, Guidelines, Myocardial ischaemia, Recommendations, Medical and Health Sciences, European Society of Cardiology, Early invasive strategy, Minoca, Rivaroxaban, Stent, Enoxaparin, Triple therapy, Bypass surgery, Betablockers, Rhythm monitoring, Nitrates, Aspirin, Glycoprotein IIb/IIIa inhibitors, Heparin, Αcute cardiac care, Revascularization, Αcute coronary syndrome, Αngioplasty, Diabetes, Cangrelor, Clopidogrel, Dabigatran, Αnticoagulation, Myocardial infarction, Fondaparinux, Αpixaban, Dual antithrombotic therapy, Bleedings, Non-ST-elevation myocardial infarction, Αntiplatelet, Clinical Medicine, Edoxaban, Bivalirudin, Prasugrel, Unstable angina
Published
2021

22. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy

Author

Glikson, Michael, primary, Nielsen, Jens Cosedis, additional, Kronborg, Mads Brix, additional, Michowitz, Yoav, additional, Auricchio, Angelo, additional, Barbash, Israel Moshe, additional, Barrabés, José A., additional, Boriani, Giuseppe, additional, Braunschweig, Frieder, additional, Brignole, Michele, additional, Burri, Haran, additional, Coats, Andrew J. S., additional, Deharo, Jean-Claude, additional, Delgado, Victoria, additional, Diller, Gerhard-Paul, additional, Israel, Carsten W., additional, Keren, Andre, additional, Knops, Reinoud E., additional, Kotecha, Dipak, additional, Leclercq, Christophe, additional, Merkely, Béla, additional, Starck, Christoph, additional, Thylén, Ingela, additional, Tolosana, José Maria, additional, Leyva, Francisco, additional, Linde, Cecilia, additional, Abdelhamid, Magdy, additional, Aboyans, Victor, additional, Arbelo, Elena, additional, Asteggiano, Riccardo, additional, Barón-Esquivias, Gonzalo, additional, Bauersachs, Johann, additional, Biffi, Mauro, additional, Birgersdotter-Green, Ulrika, additional, Bongiorni, Maria Grazia, additional, Borger, Michael A., additional, Čelutkienė, Jelena, additional, Cikes, Maja, additional, Daubert, Jean-Claude, additional, Drossart, Inga, additional, Ellenbogen, Kenneth, additional, Elliott, Perry M., additional, Fabritz, Larissa, additional, Falk, Volkmar, additional, Fauchier, Laurent, additional, Fernández-Avilés, Francisco, additional, Foldager, Dan, additional, Gadler, Fredrik, additional, De Vinuesa, Pastora Gallego Garcia, additional, Gorenek, Bulent, additional, Guerra, Jose M., additional, Hermann Haugaa, Kristina, additional, Hendriks, Jeroen, additional, Kahan, Thomas, additional, Katus, Hugo A., additional, Konradi, Aleksandra, additional, Koskinas, Konstantinos C., additional, Law, Hannah, additional, Lewis, Basil S., additional, Linker, Nicholas John, additional, Løchen, Maja-Lisa, additional, Lumens, Joost, additional, Mascherbauer, Julia, additional, Mullens, Wilfried, additional, Nagy, Klaudia Vivien, additional, Prescott, Eva, additional, Raatikainen, Pekka, additional, Rakisheva, Amina, additional, Reichlin, Tobias, additional, Ricci, Renato Pietro, additional, Shlyakhto, Evgeny, additional, Sitges, Marta, additional, Sousa-Uva, Miguel, additional, Sutton, Richard, additional, Suwalski, Piotr, additional, Svendsen, Jesper Hastrup, additional, Touyz, Rhian M., additional, Van Gelder, Isabelle C., additional, Vernooy, Kevin, additional, Waltenberger, Johannes, additional, Whinnett, Zachary, additional, and Witte, Klaus K., additional

Published
2021
Full Text
View/download PDF

23. Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombosis, and the ESC working group on cardiovascular pharmacotherapy

Author

Aboyans, Victor, primary, Bauersachs, Rupert, additional, Mazzolai, Lucia, additional, Brodmann, Marianne, additional, Palomares, José F Rodriguez, additional, Debus, Sebastian, additional, Collet, Jean-Philippe, additional, Drexel, Heinz, additional, Espinola-Klein, Christine, additional, Lewis, Basil S, additional, Roffi, Marco, additional, Sibbing, Dirk, additional, Sillesen, Henrik, additional, Stabile, Eugenio, additional, Schlager, Oliver, additional, and De Carlo, Marco, additional

Published
2021
Full Text
View/download PDF

25. The effect of intravenous ferric carboxymaltose on heatlh-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study

Author

Jankowska, Ewa A. Kirwan, Bridget-Anne Kosiborod, Mikhail and Butler, Javed Anker, Stefan D. McDonagh, Theresa Dorobantu, Maria Drozdz, Jaroslaw Filippatos, Gerasimos Keren, Andre and Khintibidze, Irakli Kragten, Hans Martinez, Felipe A. and Metra, Marco Milicic, Davor Nicolau, Jose C. Ohlsson, Marcus and Parkhomenko, Alexander Pascual-Figal, Domingo A. Ruschitzka, Frank Sim, David Skouri, Hadi van der Meer, Peter Lewis, Basil S. Comin-Colet, Josep von Haehling, Stephan and Cohen-Solal, Alain Danchin, Nicolas Doehner, Wolfram Dargie, Henry J. Motro, Michael Friede, Tim Fabien, Vincent and Dorigotti, Fabio Pocock, Stuart Ponikowski, Piotr AFFIRM-AHF Investigators

Abstract

Aims Patients with heart failure (HF) and iron deficiency experience poor health-related quality of life (HRQoL). We evaluated the impact of intravenous (IV) ferric carboxymaltose (FCM) vs. placebo on HRQoL for the AFFIRM-AHF population. Methods and results The baseline 12-item Kansas City Cardiomyopathy Questionnaire (KCCQ-12), which was completed for 1058 (535 and 523) patients in the FCM and placebo groups, respectively, was administered prior to randomization and at Weeks 2, 4, 6, 12, 24, 36, and 52. The baseline KCCQ-12 overall summary score (OSS) mean +/- standard error was 38.7 +/- 0.9 (FCM group) and 37.1 +/- 0.8 (placebo group); corresponding values for the clinical summary score (CSS) were 40.9 +/- 0.9 and 40.1 +/- 0.9. At Week 2, changes in OSS and CSS were similar for FCM and placebo. From Week 4 to Week 24, patients assigned to FCM had significantly greater improvements in OSS and CSS scores vs. placebo [adjusted mean difference (95% confidence interval, CI) at Week 4: 2.9 (0.5-5.3, P = 0.018) for OSS and 2.8 (0.3-5.3, P = 0.029) for CSS; adjusted mean difference (95% CI) at Week 24: 3.0 (0.3-5.6, P = 0.028) for OSS and 2.9 (0.2-5.6, P = 0.035) for CSS]. At Week 52, the treatment effect had attenuated but remained in favour of FCM. Conclusion In iron-deficient patients with HF and left ventricular ejection fraction

Published
2021

26. 2021 ESC/EACTS Guidelines for the management of valvular heart disease

Author

Vahanian, Alec, Beyersdorf, Friedhelm, Praz, Fabien, Milojevic, Milan, Baldus, Stephan, Bauersachs, Johann, Capodanno, Davide, Conradi, Lenard, de Bonis, Michele, de Paulis, Ruggero, Delgado, Victoria, Freemantle, Nick, Gilard, Martine, Haugaa, Kristina H., Jeppsson, Anders, Jüni, Peter, Pierard, Luc, Prendergast, Bernard D., Sadaba, J. Rafael, Tribouilloy, Christophe, Wojakowski, Wojtek, Neumann, Franz-Josef, Myers, Patrick, Abdelhamid, Magdy, Achenbach, Stephan, Asteggiano, Riccardo, Barili, Fabio, Borger, Michael A., Carrel, Thierry, Collet, Jean-Philippe, Foldager, Dan, Habib, Gilbert, Hassager, Christian, Irs, Alar, Iung, Bernard, Jahangiri, Marjan, Katus, Hugo A., Koskinas, Konstantinos C., Massberg, Steffen, Mueller, Christian E., Nielsen, Jens Cosedis, Pibarot, Philippe, Rakisheva, Amina, Roffi, Marco, Rubboli, Andrea, Shlyakhto, Evgeny, Siepe, Matthias, Sitges, Marta, Sondergaard, Lars, Sousa-Uva, Miguel, Tarantini, Guiseppe, Zamorano, Jose Luis, Benchabi, Yasmina, Chilingaryan, Aram, Metzler, Bernhard, Rustamova, Yasmin, Shumavets, Vadim, Lancellotti, Patrizio, Smajic, Elnur, Trendafilova-Lazarova, Diana, Samardzic, Jure, Karakyriou, Maria, Palecek, Tomas, Dahl, Jordi Sanchez, Meshaal, Marwa Sayed, Palm, Kairit, Virtanen, Marko, Bouleti, Claire, Bakhutashvili, Zviad, Boutsikou, Maria, Kertész, Attila B. la, Danielsen, Ragnar, Topilsky, Yan, Golino, Paolo, Tuleutayev, Rustem, Elezi, Shpend, Kerimkulova, Alina, Rudzitis, Ainars, Glaveckaite, Sigita, Sow, Rouguiatou, Demarco, Daniela Cassar, Bulatovic, Nebojsa, Aouad, Aicha, van den Brink, Renée, Antova, Emilija, Beitnes, Jan Otto, Ochala, Andrzej, Ribeiras, Regina, Vinereanu, Dragos, Irtyuga, Olga, Ivanovic, Branislava, Simkova, Iveta, Gomez, Ariana Gonzalez, Sarno, Giovanna, Pedrazzini, Giovanni B., Bsata, Walid, Zakhama, Lilia, Korkmaz, Levent, Cherniuk, Sergii, Khanji, Mohammed Y., Sharipov, Islamjan, Baigent, Colin, Aboyans, Victor, Antoniou, Sotiris, Arbelo, Elena, Baumbach, Andreas, Čelutkiene, Jelena, Cikes, Maja, Falk, Volkmar, Fauchier, Laurent, Gale, Chris P., Halvorsen, Sigrun, Jaarsma, Tiny, Konradi, Aleksandra, Kotecha, Dipak, Landmesser, Ulf, Lewis, Basil S., Linhart, Ales, Løchen, Maja-Lisa, Neubeck, Lis, Petersen, Steffen E., Prescott, Eva, Touyz, Rhian M., Galletti, Lorenzo, Hazekamp, Mark, Licht, Peter, Perier, Patrick, Prager, Richard, Roessner, Eric, Tsagakis, Konstantinos, Zientara, Alicja, Čelutkienė, Jelena, Glaveckaitė, Sigita, Vahanian, Alec, Beyersdorf, Friedhelm, Praz, Fabien, Milojevic, Milan, Baldus, Stephan, Bauersachs, Johann, Capodanno, Davide, Conradi, Lenard, De Bonis, Michele, De Paulis, Ruggero, Delgado, Victoria, Freemantle, Nick, Gilard, Martine, Haugaa, Kristina H, Jeppsson, Ander, Jüni, Peter, Pierard, Luc, Prendergast, Bernard D, Sádaba, J Rafael, Tribouilloy, Christophe, Wojakowski, Wojtek, Vahanian, A., Beyersdorf, F., Praz, F., Milojevic, M., Baldus, S., Bauersachs, J., Capodanno, D., Conradi, L., de Bonis, M., de Paulis, R., Delgado, V., Freemantle, N., Gilard, M., Haugaa, K. H., Jeppsson, A., Juni, P., Pierard, L., Prendergast, B. D., Sadaba, J. R., Tribouilloy, C., Wojakowski, W., Cardiology, and ACS - Amsterdam Cardiovascular Sciences

Subjects
Pulmonary and Respiratory Medicine, medicine.medical_specialty, Valve surgery, valve surgery, aortic regurgitation, aortic stenosis, Guidelines, mitral regurgitation, mitral stenosis, percutaneous valve intervention, prosthetic heart valves, tricuspid regurgitation, tricuspid stenosis, valve disease, valvular heart disease, Cardiology, Heart Valve Diseases, Tricuspid stenosis, Mitral valve stenosis, Tricuspid Valve Insufficiency, Internal medicine, Myocardial Revascularization, Medicine, Humans, 610 Medicine & health, Heart Valve Prosthesis Implantation, Mitral regurgitation, business.industry, Mitral Valve Insufficiency, General Medicine, medicine.disease, Aortic valve stenosis, Surgery, Cardiology and Cardiovascular Medicine, business, Valve disease
Published
2021

27. 2020 ESC guidelines on sports cardiology and exercise in patients with cardiovascular disease : The Task Force on sports cardiology and exercise in patients with cardiovascular disease of the European Society of Cardiology (ESC)

Author

Pelliccia, Antonio, Sharma, Sanjay, Gati, Sabiha, Bäck, Maria, Börjesson, Mats, Caselli, Stefano, Collet, Jean-Philippe, Corrado, Domenico, Drezner, Jonathan A., Halle, Martin, Hansen, Dominique, Heidbüchel, Hein, Myers, Jonathan, Niebauer, Josef, Papadakis, Michael, Piepoli, Massimo Francesco, Prescott, Eva, Roos-Hesselink, Jolien W., Graham Stuart, A., Taylor, Rod S., Thompson, Paul D., Tiberi, Monica, Vanhees, Luc, Wilhelm, Matthias, Guazzi, Marco, La Gerche, André, Aboyans, Victor, Adami, Paolo Emilio, Backs, Johannes, Baggish, Aaron, Basso, Cristina, Biffi, Alessandro, Bucciarelli-Ducci, Chiara, Camm, A. John, Claessen, Guido, Delgado, Victoria, Elliott, Perry M., Galderisi, Maurizio, Gale, Chris P., Gray, Belinda, Haugaa, Kristina Hermann, Iung, Bernard, Katus, Hugo A., Keren, Andre, Leclercq, Christophe, Lewis, Basil S., Mont, Lluis, Mueller, Christian, Petersen, Steffen E., Petronio, Anna Sonia, Roffi, Marco, Savonen, Kai, Serratosa, Luis, Shlyakhto, Evgeny, Simpson, Iain A., Sitges, Marta, Solberg, Erik Ekker, Sousa-Uva, Miguel, van Craenenbroeck, Emeline, Van De Heyning, Caroline, Wijns, William, and ESC Scientific Document Group

Subjects
Human medicine
Published
2021

28. The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study

Author

Jankowska, Ewa A, primary, Kirwan, Bridget-Anne, additional, Kosiborod, Mikhail, additional, Butler, Javed, additional, Anker, Stefan D, additional, McDonagh, Theresa, additional, Dorobantu, Maria, additional, Drozdz, Jarosław, additional, Filippatos, Gerasimos, additional, Keren, Andre, additional, Khintibidze, Irakli, additional, Kragten, Hans, additional, Martinez, Felipe A, additional, Metra, Marco, additional, Milicic, Davor, additional, Nicolau, José C, additional, Ohlsson, Marcus, additional, Parkhomenko, Alexander, additional, Pascual-Figal, Domingo A, additional, Ruschitzka, Frank, additional, Sim, David, additional, Skouri, Hadi, additional, van der Meer, Peter, additional, Lewis, Basil S, additional, Comin-Colet, Josep, additional, von Haehling, Stephan, additional, Cohen-Solal, Alain, additional, Danchin, Nicolas, additional, Doehner, Wolfram, additional, Dargie, Henry J, additional, Motro, Michael, additional, Friede, Tim, additional, Fabien, Vincent, additional, Dorigotti, Fabio, additional, Pocock, Stuart, additional, and Ponikowski, Piotr, additional

Published
2021
Full Text
View/download PDF

29. Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants

Author

Bosch, Jackie, primary, Lonn, Eva M, additional, Jung, Hyejung, additional, Zhu, Jun, additional, Liu, Lisheng, additional, Lopez-Jaramillo, Patricio, additional, Pais, Prem, additional, Xavier, Denis, additional, Diaz, Rafael, additional, Dagenais, Gilles, additional, Dans, Antonio, additional, Avezum, Alvaro, additional, Piegas, Leopoldo S, additional, Parkhomenko, Alexander, additional, Keltai, Kati, additional, Keltai, Matyas, additional, Sliwa, Karen, additional, Held, Claus, additional, Peters, Ronald J G, additional, Lewis, Basil S, additional, Jansky, Petr, additional, Yusoff, Khalid, additional, Khunti, Kamlesh, additional, Toff, William D, additional, Reid, Christopher M, additional, Varigos, John, additional, Joseph, Philip, additional, Leiter, Lawrence A, additional, and Yusuf, Salim, additional

Published
2021
Full Text
View/download PDF

30. CARDIAC MAGNETIC RESONANCE IMAGING FOR GUIDING DECISION-MAKING ON TREATMENT DURATION: DATA FROM RHAPSODY, A PHASE 3 CLINICAL TRIAL OF RILONACEPT IN RECURRENT PERICARDITIS

Author

Cremer, Paul, primary, Lin, David, additional, Wheeler, Alistair, additional, Abbate, Antonio, additional, Brucato, Antonio, additional, Fang, Fang, additional, Insalaco, Antonella, additional, LeWinter, Martin, additional, Lewis, Basil S., additional, Luis, Sushil, additional, Nicholls, Stephen J., additional, Petersen, John, additional, Klein, Allan, additional, Imazio, Massimo, additional, and Paolini, John F., additional

Published
2021
Full Text
View/download PDF

31. TAPERING AND DISCONTINUATION OF BACKGROUND THERAPIES DURING THE TRANSITION TO RILONACEPT MONOTHERAPY IN RHAPSODY, A PHASE 3 CLINICAL TRIAL OF RILONACEPT IN PATIENTS WITH RECURRENT PERICARDITIS

Author

Brucato, Antonio, primary, Wheeler, Alistair, additional, Luis, Sushil, additional, Abbate, Antonio, additional, Cremer, Paul, additional, Fang, Fang, additional, Insalaco, Antonella, additional, LeWinter, Martin, additional, Lewis, Basil S., additional, Lin, David, additional, Nicholls, Stephen J., additional, Klein, Allan, additional, Imazio, Massimo, additional, and Paolini, John F., additional

Published
2021
Full Text
View/download PDF

32. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial

Author

Alexander, John H., Lopes, Renato D., Thomas, Laine, Alings, Marco, Atar, Dan, Aylward, Philip, Goto, Shinya, Hanna, Michael, Huber, Kurt, Husted, Steen, Lewis, Basil S., McMurray, John J.V., Pais, Prem, Pouleur, Hubert, Steg, Philippe Gabriel, Verheugt, Freek W.A., Wojdyla, Daniel M., Granger, Christopher B., and Wallentin, Lars

Published
2014
Full Text
View/download PDF

33. Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fraction.

Author

Saldarriaga, Clara, Atar, Dan, Stebbins, Amanda, Lewis, Basil S., Abidin, Imran Zainal, Blaustein, Robert O., Butler, Javed, Ezekowitz, Justin A., Hernandez, Adrian F., Lam, Carolyn S.P., O'Connor, Christopher M., Pieske, Burkert, Ponikowski, Piotr, Roessig, Lothar, Voors, Adriaan A., Anstrom, Kevin J., and Armstrong, Paul W.

Abstract

Aims: Coronary artery disease (CAD) portends worse outcomes in heart failure (HF). We aimed to characterize patients with CAD and worsening HF with reduced ejection fraction (HFrEF) and evaluate post hoc whether vericiguat treatment effect varied according to CAD. Methods and results: Cox proportional hazards were generated for the primary endpoint of cardiovascular death or HF hospitalization (CVD/HFH). CAD was defined as previous myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting. Of 5048 patients in VICTORIA with available data on CAD status, 2704 had CAD and were older, were more frequently male, diabetic, and had a lower glomerular filtration rate than those without CAD (all p <0.0001). Use of implantable cardioverter defibrillators and cardiac resynchronization therapy (CRT) was higher in patients with versus without CAD (33.5% vs. 21.1%; p <0.0001 and 16.3% vs. 12.8%; p = 0.0006). The primary endpoint of CVD/HFH was higher in those with versus without CAD (40.6 vs. 30.1/100 patient‐years; adjusted hazard ratio [HR] 1.23; p <0.001) as was all‐cause mortality (17.9% vs. 12.7%; adjusted HR 1.32; p <0.001). The primary outcome of CVD/HFH associated with vericiguat in patients with or without CAD was 38.8 versus 27.6 per 100 patient‐years and for placebo was 42.6 versus 32.7 per 100 patient‐years (interaction p = 0.78). Conclusion: In this post hoc study, CAD was associated with more CVD and HFH in patients with HFrEF and worsening HF. Vericiguat was beneficial and safe regardless of concomitant CAD. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

35. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European respiratory society (ERS) : The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC)

Author

Konstantinides, Stavros V., Meyer, Guy, Bueno, Hector, Galié, Nazzareno, Gibbs, J. Simon R., Ageno, Walter, Agewall, Stefan, Almeida, Ana G., Andreotti, Felicita, Barbato, Emanuele, Baumbach, Andreas, Beygui, Farzin, Carlsen, Jørn, De Carlo, Marco, Delcroix, Marion, Subias, Pilar Escribano, Gaine, Sean, Goldhaber, Samuel Z., Gopalan, Deepa, Habib, Gilbert, Jenkins, David, Kjellström, Barbro, Lainscak, Mitja, Lee, Geraldine, Le Gal, Grégoire, Messas, Emmanuel, Morais, Joao, Piepoli, Massimo Francesco, Price, Susanna, Salvi, Aldo, Sanchez, Olivier, Stortecky, Stefan, Thielmann, Matthias, Noordegraaf, Anton Vonk, Becattini, Cecilia, Bueno, Héctor, Geersing, Geert Jan, Harjola, Veli Pekka, Huisman, Menno V., Humbert, Marc, Jennings, Catriona Sian, Jiménez, David, Kucher, Nils, Lang, Irene Marthe, Lankeit, Mareike, Lorusso, Roberto, Mazzolai, Lucia, Meneveau, Nicolas, Áinle, Fionnuala Ní, Prandoni, Paolo, Pruszczyk, Piotr, Righini, Marc, Torbicki, Adam, Van Belle, Eric, Zamorano, José Luis, Windecker, Stephan, Aboyans, Victor, Baigent, Colin, Collet, Jean Philippe, Dean, Veronica, Delgado, Victoria, Fitzsimons, Donna, Gale, Chris P., Grobbee, Diederick E., Hindricks, Gerhard, Iung, Bernard, Jüni, Peter, Katus, Hugo A., Landmesser, Ulf, Leclercq, Christophe, Lettino, Maddalena, Lewis, Basil S., Merkely, Bela, Mueller, Christian, Petersen, Steffen E., Petronio, Anna Sonia, Richter, Dimitrios J., Roffi, Marco, Shlyakhto, Evgeny, Simpson, Iain A., Sousa-Uva, Miguel, Touyz, Rhian M., Hammoudi, Naima, Hayrapetyan, Hamlet, Mascherbauer, Julia, Ibrahimov, Firdovsi, Polonetsky, Oleg, Lancellotti, Patrizio, Tokmakova, Mariya, Skoric, Bosko, Michaloliakos, Ioannis, Hutyra, Martin, Mellemkjaer, Søren, Mansour, Mostafa, Reinmets, Julia, Jääskeläinen, Pertti, Angoulvant, Denis, Bauersachs, Johann, Giannakoulas, George, Zima, Endre, Vizza, Carmine Dario, Sugraliyev, Akhmetzhan, Bytyçi, Ibadete, Maca, Aija, Ereminiene, Egle, Huijnen, Steve, Xuereb, Robert, Diaconu, Nadejda, Bulatovic, Nebojsa, Asfalou, Ilyasse, Bosevski, Marijan, Halvorsen, Sigrun, Sobkowicz, Bozena, Ferreira, Daniel, Petris, Antoniu Octavian, Moiseeva, Olga, Zavatta, Marco, Obradovic, Slobodan, Šimkova, Iveta, Radsel, Peter, Ibanez, Borja, Wikström, Gerhard, Aujesky, Drahomir, Kaymaz, Cihangir, Parkhomenko, Alexander, and Pepke-Zaba, Joanna

Subjects
thrombolysis, pulmonary embolism, treatment, diagnosis, education, venous thromboembolism, biomarkers, heart failure, shock, Embolectomy, Guidelines, dyspnoea, right ventricle, humanities, Anticoagulation, Pregnancy, Venous thrombosis, Journal Article, echocardiography, Cardiology and Cardiovascular Medicine, health care economics and organizations, Risk assessment
Abstract

Guidelines summarize and evaluate available evidence with the aim of assisting health professionals in proposing the best management strategies for an individual patient with a given condition. Guidelines and their recommendations should facilitate decision making of health professionals in their daily practice. However, the final decisions concerning an individual patient must be made by the responsible health professional(s) in consultation with the patient and caregiver as appropriate.

Published
2020

36. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

Author

Mach, François, Baigent, Colin, Catapano, Alberico L, Koskinas, Konstantinos C, Casula, Manuela, Badimon, Lina, Chapman, M John, De Backer, Guy G, Delgado, Victoria, Ference, Brian A, Graham, Ian M, Halliday, Alison, Landmesser, Ulf, Mihaylova, Borislava, Pedersen, Terje R, Riccardi, Gabriele, Richter, Dimitrios J, Sabatine, Marc S, Taskinen, Marja-Riitta, Tokgozoglu, Lale, Wiklund, Olov, Mueller, Christian, Drexel, Heinz, Aboyans, Victor, Corsini, Alberto, Doehner, Wolfram, Farnier, Michel, Gigante, Bruna, Kayikcioglu, Meral, Krstacic, Goran, Lambrinou, Ekaterini, Lewis, Basil S, Masip, Josep, Moulin, Philippe, Petersen, Steffen, Petronio, Anna Sonia, Piepoli, Massimo Francesco, Pintó, Xavier, Räber, Lorenz, Ray, Kausik K, Reiner, Željko, Riesen, Walter F, Roffi, Marco, Schmid, Jean- Paul, Shlyakhto, Evgeny, Simpson, Iain A, Stroes, Erik, Sudano, Isabella, Tselepis, Alexandros D, Viigimaa, Margus, Vindis, Cecile, Vonbank, Alexander, Vrablik, Michal, Vrsalovic, Mislav, Zamorano, José Luis, Collet, Jean- Philippe, John Chapman, M, Windecker, Stephan, Collet, Jean-Philippe, Dean, Veronica, Fitzsimons, Donna, Gale, Chris P, Grobbee, Diederick, Halvorsen, Sigrun, Hindricks, Gerhard, Iung, Bernard, Jüni, Peter, Katus, Hugo A, Leclercq, Christophe, Lettino, Maddalena, Merkely, Bela, Sousa-Uva, Miguel, Touyz, Rhian M, Nibouche, Djamaleddine, Zelveian, Parounak H, Siostrzonek, Peter, Najafov, Ruslan, van de Borne, Philippe, Pojskic, Belma, Postadzhiyan, Arman, Kypris, Lambros, Špinar, Jindřich, Larsen, Mogens Lytken, Eldin, Hesham Salah, Strandberg, Timo E, Ferrières, Jean, Agladze, Rusudan, Laufs, Ulrich, Rallidis, Loukianos, Bajnok, László, Gudjónsson, Thorbjörn, Maher, Vincent, Henkin, Yaakov, Gulizia, Michele Massimo, Mussagaliyeva, Aisulu, Bajraktari, Gani, Kerimkulova, Alina, Latkovskis, Gustavs, Hamoui, Omar, Slapikas, Rimvydas, Visser, Laurent, Dingli, Philip, Ivanov, Victoria, Boskovic, Aneta, Nazzi, Mbarek, Visseren, Frank, Mitevska, Irena, Retterstøl, Kjetil, Jankowski, Piotr, Fontes-Carvalho, Ricardo, Gaita, Dan, Ezhov, Marat, Foscoli, Marina, Giga, Vojislav, Pella, Daniel, Fras, Zlatko, de Isla, Leopoldo Perez, Hagström, Emil, Lehmann, Roger, Abid, Leila, Ozdogan, Oner, Mitchenko, Olena, Patel, Riyaz S, ESC Scientific Document Group, Service d’Endocrinologie, Métabolisme et Prévention des Risques Cardio-Vasculaires [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Sorbonne Université - Faculté de Médecine (SU FM), Sorbonne Université (SU), University of Zurich, and Mach, François

Subjects
medicine.medical_specialty, Treatment adherence, Evinacumab, [SDV]Life Sciences [q-bio], Very low-density lipoproteins, 610 Medicine & health, Lipoprotein remnants, 030204 cardiovascular system & hematology, Guidelines, Total cardiovascular risk, 2705 Cardiology and Cardiovascular Medicine, Treatment (lifestyle), 03 medical and health sciences, 0302 clinical medicine, Risk Factors, medicine, Humans, 030212 general & internal medicine, High-density lipoproteins, Intensive care medicine, ComputingMilieux_MISCELLANEOUS, Dyslipidaemias, Triglycerides, Dyslipidemias, Task force, business.industry, Treatment (drugs), Lipids, Coronary heart disease, 3. Good health, Treatment (adherence), Cholesterol, Cardiovascular Diseases, Heart Disease Risk Factors, 10209 Clinic for Cardiology, European atherosclerosis society, LDL Cholesterol Lipoproteins, Low-density lipoproteins, Lipid modification, Cardiology and Cardiovascular Medicine, business, Familial hypercholesterolaemia, Apolipoprotein B, All cause mortality, Guidelines • dyslipidaemias • cholesterol • triglycerides • low-density lipoproteins • high-density lipoproteins • apolipoprotein B • lipoprotein(a) • lipoprotein remnants • total cardiovascular risk • treatment (lifestyle) • treatment (drugs) • treatment (adherence) • very low-density lipoproteins • familial hypercholesterolaemia, Lipoprotein(a)
Abstract

The previous ESC/EAS lipid Guidelines were published in August 2016. The emergence of a substantial body of evidence over the last few years has required new, up-to-date Guidelines. New evidence has confirmed that the key initiating event in atherogenesis is the retention of low- density lipoprotein (LDL) cholesterol (LDL-C) and other cholesterol-rich apolipoprotein (Apo) B containing lipoproteins within the arterial wall. Several recent placebo-controlled clinical studies have shown that the addition of either ezetimibe or anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) to statin therapy provides a further reduction in atherosclerotic cardiovascular disease (ASCVD) risk, which is directly and positively correlated with the incrementally achieved absolute LDL-C reduction. Furthermore, these clinical trials have clearly indicated that the lower the achieved LDL-C values, the lower the risk of future cardiovascular (CV) events, with no lower limit for LDL-C values, or ‘J’-curve effect.

Published
2020
Full Text
View/download PDF

37. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS) : the Task Force for the diagnosis and management of atrialfibrillation of the European Society of Cardiology (ESC) : developed with the special contribution of the European HeartRhythm Association (EHRA) of the ESC

Author

Hindricks, Gerhard, Potpara, Tatjana, Dagres, Nikolaos, Arbelo, Elena, Bax, Jeroen J., Blomström-Lundqvist, Carina, Boriani, Giuseppe, Castella, Manuel, Dan, Gheorghe-Andrei, Dilaveris, Polychronis E., Fauchier, Laurent, Petersen, Steffen E., Piccini, Jonathan P., Popescu, Bogdan A., Pürerfellner, Helmut, Richter, Dimitrios J., Roffi, Marco, Rubboli, Andrea, Scherr, Daniel, Schnabel, Renate B., Simpson, Iain A., Raatikainen, Pekka, Shlyakhto, Evgeny, Sinner, Moritz F., Steffel, Jan, Suwalski, Piotr, Svetlosak, Martin, Touyz, Rhian M., Windecker, Stephan, Baigent, Colin, Collet, Jean-Philippe, Dean, Veronica, Boveda, Serge, Fitzsimons, Donna, Gale, Chris P., Grobbee, Diederick E., Halvorsen, Sigrun, Lung, Bernard, Jüni, Peter, Petronio, Anna Sonia, Sousa Uva, Miguel, Delassi, Tahar, Sisakian, Hamayak S., Papiashvili, Giorgi, Chasnoits, Alexandr, De Pauw, Michel, Smajić, Elnur, Shalganov, Tchavdar, Avraamides, Panayiotis, Kautzner, Josef, Gerdes, Christian, Alaziz, Ahmad Abd, Kampus, Priit, Vassilikos, Vassilios P., Csanádi, Zoltán, Arnar, David O., Galvin, Joseph, Barsheshet, Alon, Caldarola, Pasquale, Rakisheva, Amina, Filippatos, Gerasimos, Bytyçi, Ibadete, Kerimkulova, Alina, Kalejs, Oskars, Njeim, Mario, Puodziukynas, Aras, Groben, Laurent, Sammut, Mark A., Grosu, Aurel, Boskovic, Aneta, Moustaghfir, Abdelhamid, Kalman, Jonathan M., de Groot, Natasja, Poposka, Lidija, Anfinsen, Ole-Gunnar, Mitkowski, Przemyslaw P., Cavaco, Diogo, Siliste, Calin, Mikhaylov, Evgeny N., Bertelli, Luca, Kojic, Dejan, Hatala, Robert, La Meir, Mark, Fras, Zlatko, Arribas, Fernando, Juhlin, Tord, Sticherling, Christian, Abid, Leila, Atar, Ilyas, Sychov, Oleg, Bates, Matthew G. D., Zakirov, Nodir U., Lane, Deirdre A., Lebeau, Jean-Pierre, Lettino, Maddalena, Lip, Gregory Y. H., Pinto, Fausto J., Thomas, G. Neil, Valgimigli, Marco, Van Gelder, Isabelle C., Van Putte, Bart P., Watkins, Caroline L., Kirchhof, Paulus, Kühne, Michael, Aboyans, Victor, Ahlsson, Anders, Balsam, Pawel, Bauersachs, Johann, Benussi, Stefano, Brandes, Axel, Braunschweig, Frieder, Camm, A. John, Capodanno, Davide, Casadei, Barbara, Conen, David, Crijns, Harry J. G. M., Delgado, Victoria, Dobrev, Dobromir, Drexel, Heinz, Eckardt, Lars, Folliguet, Thierry, Gorenek, Bulent, Haeusler, Karl Georg, Heidbuchel, Hein, Iung, Bernard, Katus, Hugo A., Kotecha, Dipak, Landmesser, Ulf, Leclercq, Christophe, Lewis, Basil S., Mascherbauer, Julia, Merino, Jose Luis, Merkely, Béla, Mont, Lluís, Mueller, Christian, Nagy, Klaudia V., Oldgren, Jonas, Pavlović, Nikola, Pedretti, Roberto F. E., and Repositório da Universidade de Lisboa

Subjects
Rate control, AF surgery, Guidelines, Upstream therapy, Recommendations, Left atrial appendage occlusion, Atrial fibrillation, Pulmonary vein isolation, Left atrial ablation, Antiarrhythmic drugs, Cardioversion, Stroke, Anticoagulation, Vitamin K antagonists, Screening, Non-vitamin K antagonist oral anticoagulants, Rhythm control, Catheter ablation, ABC pathway
Abstract

© 2020 European Society of Cardiology. All rights reserved., Atrial fibrillation (AF) poses significant burden to patients, physicians, and healthcare systems globally. Substantial research efforts and resources are being directed towards gaining detailed information about the mechanisms underlying AF, its natural course and effective treatments (see also the ESC Textbook of Cardiovascular Medicine: CardioMed) and new evidence is continuously generated and published. The complexity of AF requires a multifaceted, holistic, and multidisciplinary approach to the management of AF patients, with their active involvement in partnership with clinicians. Streamlining the care of patients with AF in daily clinical practice is a challenging but essential requirement for effective management of AF. In recent years, substantial progress has been made in the detection of AF and its management, and new evidence is timely integrated in this third edition of the ESC guidelines on AF. The 2016 ESC AF Guidelines introduced the concept of the five domains to facilitate an integrated structured approach to AF care and promote consistent, guideline-adherent management for all patients. The Atrial Fibrillation Better Care (ABC) approach in the 2020 ESC AF Guidelines is a continuum of this approach, with the goal to further improve the structured management of AF patients, promote patient values, and finally improve patient outcomes.

Published
2020

39. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)

Author

Hindricks, Gerhard, Potpara, Tatjana, Dagres, Nikolaos, Arbelo, Elena, Bax, Jeroen J, Blomström-Lundqvist, Carina, Boriani, Giuseppe, Castella, Manuel, Dan, Gheorghe-Andrei, Dilaveris, Polychronis E, Fauchier, Laurent, Filippatos, Gerasimos, Kalman, Jonathan M, La Meir, Mark, Lane, Deirdre A, Lebeau, Jean-Pierre, Lettino, Maddalena, Lip, Gregory Y H, Pinto, Fausto J, Thomas, G Neil, Valgimigli, Marco, Van Gelder, Isabelle C, Van Putte, Bart P, Watkins, Caroline L, Kirchhof, Paulus, Kühne, Michael, Aboyans, Victor, Ahlsson, Anders, Balsam, Pawel, Bauersachs, Johann, Benussi, Stefano, Brandes, Axel, Braunschweig, Frieder, Camm, A John, Capodanno, Davide, Casadei, Barbara, Conen, David, Crijns, Harry J G M, Delgado, Victoria, Dobrev, Dobromir, Drexel, Heinz, Eckardt, Lars, Fitzsimons, Donna, Folliguet, Thierry, Gale, Chris P, Gorenek, Bulent, Haeusler, Karl Georg, Heidbuchel, Hein, Iung, Bernard, Katus, Hugo A, Kotecha, Dipak, Landmesser, Ulf, Leclercq, Christophe, Lewis, Basil S, Mascherbauer, Julia, Merino, Jose Luis, Merkely, Béla, Mont, Lluís, Mueller, Christian, Nagy, Klaudia V, Oldgren, Jonas, Pavlović, Nikola, Pedretti, Roberto F E, Petersen, Steffen E, Piccini, Jonathan P, Popescu, Bogdan A, Pürerfellner, Helmut, Richter, Dimitrios J, Roffi, Marco, Rubboli, Andrea, Scherr, Daniel, Schnabel, Renate B, Simpson, Iain A, Shlyakhto, Evgeny, Sinner, Moritz F, Steffel, Jan, Sousa-Uva, Miguel, Suwalski, Piotr, Svetlosak, Martin, Touyz, Rhian M, Neil Thomas, G, CHU Trousseau [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Cardiovascular Centre (CVC), Surgical clinical sciences, and Cardiac Surgery

Subjects
left atrial ablation, left atrial appendage occlusion, AF surgery, medicine.medical_treatment, [SDV]Life Sciences [q-bio], Management of atrial fibrillation, 030204 cardiovascular system & hematology, Cardioversion, VITAMIN-K ANTAGONIST, surgery, chemistry.chemical_compound, 0302 clinical medicine, cardioversion, Edoxaban, QUALITY-OF-LIFE, antiarrhythmic drugs, OBSTRUCTIVE SLEEP-APNEA, catheter ablation, RADIOFREQUENCY CATHETER ABLATION, Medicine, atrial fibrillation, 030212 general & internal medicine, anticoagulation, reproductive and urinary physiology, ComputingMilieux_MISCELLANEOUS, pulmonary vein isolation, 0303 health sciences, rhythm control, EACTS, HEART RHYTHM SOCIETY, recommendations, Atrial fibrillation, General Medicine, non-Vitamin K antagonist oral anticoagulants, Vitamin K antagonist, PULMONARY-VEIN ISOLATION, stroke, 3. Good health, 2020 ESC Guidelines, Dronedarone, vitamin K antagonists, Cardiothoracic surgery, Cardio-Thoracic Surgery, embryonic structures, DIRECT ORAL ANTICOAGULANTS, cardiovascular system, Cardiology, Dose reduction, biological phenomena, cell phenomena, and immunity, Cardiology and Cardiovascular Medicine, medicine.drug, Quinidine, medicine.medical_specialty, medicine.drug_class, non-vitamin K antagonist oral anticoagulants, PERCUTANEOUS CORONARY INTERVENTION, Renal function, macromolecular substances, ABC pathway, Guidelines, rate control, screening, upstream therapy, Vitamin K antagonists, B700, 03 medical and health sciences, Internal medicine, Diseases of the circulatory (Cardiovascular) system, cardiovascular diseases, 030304 developmental biology, urogenital system, business.industry, medicine.disease, TRANSIENT ISCHEMIC ATTACK, ANTIARRHYTHMIC-DRUG-THERAPY, chemistry, 030228 respiratory system, Concomitant, RC666-701, business
Abstract

Supplementary Table 9, column 'Edoxaban', row 'eGFR category', '95 mL/min' (page 15). The cell should be coloured green instead of yellow. It should also read "60 mg"instead of "60 mg (use with caution in 'supranormal' renal function)."In the above-indicated cell, a footnote has also been added to state: "Edoxaban should be used in patients with high creatinine clearance only after a careful evaluation of the individual thromboembolic and bleeding risk."Supplementary Table 9, column 'Edoxaban', row 'Dose reduction in selected patients' (page 16). The cell should read "Edoxaban 60 mg reduced to 30 mg once daily if any of the following: creatinine clearance 15-50 mL/min, body weight

Published
2021

40. Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium–glucose co‐transporter 2 inhibitor therapy in DECLARE‐TIMI 58

Author

Zelniker, Thomas A., primary, Morrow, David A., additional, Mosenzon, Ofri, additional, Goodrich, Erica L., additional, Jarolim, Petr, additional, Murphy, Sabina A., additional, Bhatt, Deepak L., additional, Leiter, Lawrence A., additional, McGuire, Darren K., additional, Wilding, John, additional, Bode, Christoph, additional, Lewis, Basil S., additional, Gause‐Nilsson, Ingrid, additional, Langkilde, Anna Maria, additional, Fredriksson, Martin, additional, Raz, Itamar, additional, Sabatine, Marc S., additional, and Wiviott, Stephen D., additional

Published
2020
Full Text
View/download PDF

43. PCSK9 INHIBITION AND AORTIC STENOSIS IN THE FOURIER TRIAL

Author

Bergmark, Brian, primary, O’Donoghue, Michelle, additional, Murphy, Sabina, additional, Kuder, Julia, additional, Ezhov, Marat V., additional, Ceska, Richard, additional, Gouni-Berthold, Ioanna, additional, Jensen, Henrik Kjærulf, additional, Tokgozoglu, Sadberk Lale, additional, Mach, François, additional, Huber, Kurt, additional, Gaciong, Zbigniew, additional, Lewis, Basil S., additional, Schiele, Francois, additional, Jukema, Johan Wouter, additional, Pedersen, Terje, additional, Giugliano, Robert, additional, and Sabatine, Marc Steven, additional

Published
2020
Full Text
View/download PDF

47. Impact of Diabetes Mellitus and Chronic Kidney Disease on Cardiovascular Outcomes and Platelet P2Y 12 Receptor Antagonist Effects in Patients With Acute Coronary Syndromes: Insights From the PLATO Trial

Author

Franchi, Francesco, James, Stefan, Ghukasyan, Tatevik, Budaj, Andrzej J., Cornel, Jan H., Katus, Hugo A., Keltai, Matyas, Kontny, Frederic, Lewis, Basil S., Storey, Robert F., Himmelmann, Anders, Wallentin, Lars, Angiolillo, Dominick J., Parkhomenko, Alexander Nikolaevich, Oto, Ali, Skene, Allan, Budaj, Andrzej, Freij, Anneli, Santoso, Anwar, Armando, A, Meier, Bernhard, Yu, Cheuk Man, Cannon, Christopher P., Zambahari, Dato Seri Robaayah, Wu, Delon Wu, Ardissino, Diego, Raev, Dimitar, Kremastinos, Dimitrios, Weaver, Douglas, Paolasso, Ernesto, Giannitsis, Evangelos, Verheugt, Freek, Maurer, Gerald, Katus, Hugo, Emanuelsson, Hakan, Horrow, Jay, Bassand, Jean-Pierre, Spinar, Jindrich, Morais, Joao, Lopez Sendon, Jose, Nicolau, Jose, Seung, Ki-Bae, Teik, Lim Soo, Heras, Magda, Claeys, Marc J., Sabatine, Marc, Vintila, Marius, Ruda, Mikhail, Thorsen, Mona, Kleiman, Neil, Babilonia, Noe, Commerford, Patrick, Gurbel, Paul, Aylward, Phil, Steg, Philippe Gabriel, Theroux, Pierre, Sritara, Piyamitr, Pais, Prem, Becker, Richard, Lassila, Riitta, Harrington, Robert A., Gao, Runlin, Husted, Steen, Duris, Tibor, Chapichadze, Zaza, HUS Comprehensive Cancer Center, University Management, Department of Oncology, and PLATO Investigators

Subjects
Male, Vascular damage Radboud Institute for Health Sciences [Radboudumc 16], Comorbidity, 030204 cardiovascular system & hematology, urologic and male genital diseases, FUNCTION PROFILES, RESPONSIVENESS, Electrocardiography, 0302 clinical medicine, Risk Factors, Coronary Heart Disease, ARTERY-DISEASE, Medicine, Cardiac and Cardiovascular Systems, 030212 general & internal medicine, Myocardial infarction, Stroke, Original Research, Kardiologi, Absolute risk reduction, Diabetes, Type 2, DUAL ANTIPLATELET THERAPY, Middle Aged, Prognosis, Clopidogrel, female genital diseases and pregnancy complications, 3. Good health, Survival Rate, diabetes mellitus, Female, Cardiology and Cardiovascular Medicine, Ticagrelor, medicine.drug, Platelets, RENAL-FUNCTION, medicine.medical_specialty, Acute coronary syndrome, ANTITHROMBOTIC THERAPY, INHIBITION, acute coronary syndrome, ticagrelor, 03 medical and health sciences, Internal medicine, Diabetes mellitus, Humans, Renal Insufficiency, Chronic, Aged, Retrospective Studies, Pharmacology, clopidogrel, Dose-Response Relationship, Drug, business.industry, Thrombosis, medicine.disease, United States, REACTIVITY, 3121 General medicine, internal medicine and other clinical medicine, Purinergic P2Y Receptor Antagonists, Human medicine, business, Acute Coronary Syndromes, Platelet Aggregation Inhibitors, chronic kidney disease, Follow-Up Studies, Kidney disease
Abstract

Background There are limited data on how the combination of diabetes mellitus ( DM ) and chronic kidney disease ( CKD ) affects cardiovascular outcomes as well as response to different P2Y 12 receptor antagonists, which represented the aim of the present investigation. Methods and Results In this post hoc analysis of the PLATO (Platelet Inhibition and Patient Outcomes) trial, which randomized acute coronary syndrome patients to ticagrelor versus clopidogrel, patients (n=15 108) with available DM and CKD status were classified into 4 groups: DM +/ CKD + (n=1058), DM +/ CKD − (n=2748), DM −/ CKD + (n=2160), and DM −/ CKD − (n=9142). The primary efficacy end point was a composite of cardiovascular death, myocardial infarction, or stroke at 12 months. The primary safety end point was PLATO major bleeding. DM +/ CKD + patients had a higher incidence of the primary end point compared with DM −/ CKD − patients (23.3% versus 7.1%; adjusted hazard ratio 2.22; 95% CI 1.88–2.63; P DM +/ CKD − and DM −/ CKD + had an intermediate risk profile. The same trend was shown for the individual components of the primary end point and for major bleeding. Compared with clopidogrel, ticagrelor reduced the incidence of the primary end point consistently across subgroups ( P ‐interaction=0.264), but with an increased absolute risk reduction in DM +/ CKD +. The effects on major bleeding were also consistent across subgroups ( P ‐interaction=0.288). Conclusions In acute coronary syndrome patients, a gradient of risk was observed according to the presence or absence of DM and CKD , with patients having both risk factors at the highest risk. Although the ischemic benefit of ticagrelor over clopidogrel was consistent in all subgroups, the absolute risk reduction was greatest in patients with both DM and CKD . Clinical Trial Registration URL : http://www.clinicatrials.gov . Unique identifier: NCT 00391872.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results